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Abstract
Background: The Cox model relies on the proportional hazards (PH) assumption, implying that the factors
investigated have a constant impact on the hazard - or risk - over time. We emphasize the importance of this
assumption and the misleading conclusions that can be inferred if it is violated; this is particularly essential in the
presence of long follow-ups.
Methods: We illustrate our discussion by analyzing prognostic factors of metastases in 979 women treated for
breast cancer with surgery. Age, tumour size and grade, lymph node involvement, peritumoral vascular invasion
(PVI), status of hormone receptors (HRec), Her2, and Mib1 were considered.
Results: Median follow-up was 14 years; 264 women developed metastases. The conventional Cox model
suggested that all factors but HRec, Her2, and Mib1 status were strong prognostic factors of metastases. Additional
tests indicated that the PH assumption was not satisfied for some variables of the model. Tumour grade had a
significant time-varying effect, but although its effect diminished over time, it remained strong. Interestingly, while
the conventional Cox model did not show any significant effect of the HRec status, tests provided strong evidence
that this variable had a non-constant effect over time. Negative HRec status increased the risk of metastases early
but became protective thereafter. This reversal of effect may explain non-significant hazard ratios provided by
previous conventional Cox analyses in studies with long follow-ups.
Conclusions: Investigating time-varying effects should be an integral part of Cox survival analyses. Detecting and
accounting for time-varying effects provide insights on some specific time patterns, and on valuable biological
information that could be missed otherwise.
Background
Survival analysis, or time-to-event data analysis, is
widely used in oncology since we are often interested in
studying a delay, such as the time from cancer diagnosis
or treatment initiation to cancer recurrence or death.
Thanks to the improvement of cancer treatments, and
the induced longer life expectancy, we observe an
increasing number of studies with long follow-up peri-
ods. Statistical models to analyze such data should thus
adequately account for the increasing duration of fol-
low-ups. The Cox proportional hazards (PH) model
allows one to describe the survival time as a function of
multiple prognostic factors [1]. This model relies on a
fundamental assumption, the proportionality of the
hazards, implying that the factors investigated have a
constant impact on the hazard - or risk - over time. If
time-dependent variables are included without appropri-
ate modeling, the PH assumption is violated. As a result,
misleading effect estimates can be derived, and signifi-
cant effect in the early (or late) follow-up period may be
missed. Checking the proportionality of the hazards
should thus be an integral part of a survival analysis by
a Cox model. The assumption, however, is not systema-
tically verified. In a 1995 review of cancer publications
using a Cox model, Altman et al. reported that most
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similar findings were reported recently by one of the co-
authors of the present work [3].
Although the Cox model has been widely used (more
than 25 000 citations since the publication of the origi-
nal paper by Cox [4]), recent publications suggest a
growing interest in the quality of its applications. Special
papers in statistics have been published in the oncology
literature providing general introductions to survival
analysis [5-8]; topics covered included summarizing sur-
vival data, testing for a difference between groups, pre-
senting existing statistical models, or assessing the
adequacy of a survival model. Others works focused on
providing definition of specific survival endpoints [9], or
on the quality of reporting of survival events [3].
Assessing whether the assumption of proportional
hazards is a central theme in survival analysis, and as
such is discussed in several statistical textbooks [10-14]
as well as in the general statistical literature [15-18]. To
our knowledge however, this topic has been discussed in
few medical journals. Importantly, this strong assump-
tion does not seem to be systematically assessed. For
illustration, a recent review of clinical trials with primary
analyses based on survival end points showed that only
one of the 64 papers that used a Cox model mentioned
verifying the PH assumption [3].
Our objective is to inform clinicians, as well as those
who read and write manuscripts in medical journals,
about the importance of the underlying PH assumption,
the misleading conclusions that can be inferred if it is
violated, as well as the additional information provided
by verifying it. After a theoretical introduction, we
describe techniques to assess if this assumption is vio-
lated, and model strategies to account for, and describe
time-dependency. We illustrate our discussion with a
study on prognostic factors in breast cancer.
Methods and results
Survival analysis
In many studies, the primary variable of interest is a
delay, such as the time from cancer diagnosis to a parti-
cular event of interest. This event may be death, and for
this reason the analysis of such data is often referred to
as survival analysis. The event of interest may not have
occurred at the time of the statistical analysis, and simi-
larly, a subject may be lost to follow-up before the event
is observed. In such case, data are said to be censored at
the time of the analysis or at the time the patient was
lost to follow-up. Censored data still bring some infor-
mation since although we do not know the exact date of
t h ee v e n t ,w ek n o wt h a ti to c c u r r e dl a t e rt h a nt h ec e n -
soring time.
Both the Kaplan-Meier method and the Cox propor-
tional hazards (PH) model allow one to analyze
censored data [1,19], and to estimate the survival prob-
ability, S(t), that is the probability that a subject survives
beyond some time t. Statistically, this probability is pro-
vided by the survival function S(t) = P (T > t), where T
is the survival time. The Kaplan Meier method estimates
the survival probability non-parametrically, that is,
assuming no specific underlying function [19]. Several
tests are available to compare the survival distributions
across groups, including the log-rank and the Mann-
Whitney-Wilcoxon tests [20,21]. The Cox PH model
accounts for multiple risk factors simultaneously. It does
not posit any distribution, or shape for the survival
function, however, the instantaneous incidence rate of
the event is modeled as a function of time and risk
factors.
The instantaneous hazard rate at time t, also called
instantaneous incidence, death, or failure rate, or risk, is
the instantaneous probability of experiencing an event
at time t, given that the event has not occurred yet. It is
a rate of event per unit of time, and is allowed to vary
over time. Just as the risk of events per unit time, one
can make an analogy by considering the speed given by
a car speedometer, which represents the distance tra-
velled per unit of time. Suppose, that the event of inter-
est is death, and we are interested in its association with
n covariates, X1,X 2, ..., Xn, then the hazard is given by:
ht ht x x x xn n () () e x p ( )   01 1 2 2    (1)
The baseline hazard rate h0(t) is an unspecified non-
negative function of time. It is the time-dependent part
of the hazard and corresponds to the hazard rate when
all covariate values are equal to zero. b1, b2,. . . ,bn are
the coefficients of the regression function b1x1 + b2x2 +...
bnxn. Suppose that we are interested in a single covariate
then the hazard is:
ht ht x x() () e x p ( )  0  (2)
The hazards for two subjects with covariate values x1
and x2 are thus given respectively by hx1(t) = h0(t) exp
(bx1)a n dh x2(t) = h0(t) exp(bx2), and the hazard ratio is
expressed as:
HR h t h t x x xx   21 2 1 ( ) / ( ) exp[ ( )]  (3)
Taking x2 =x 1 + 1, the hazard ratio reduces to HR =
exp(b) and corresponds to the effect of one unit increase
in the explanatory variable X on the risk of event. Since
b =l o g ( H R ) ,b is referred as the log hazard ratio.
Although the hazard rate hx(t) is allowed to vary over
time, the hazard ratio HR is constant; this is the
assumption of proportional hazards. If the HR is greater
than 1 (b > 0), the event risk is increased for subjects
with covariate value x2 compared to subjects with
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cates a decreased risk. When the HR is not constant
over time, the variable is said to have a time-varying
effect; for example, the effect of a treatment can be
strong immediately after treatment but fades with time.
This should not be confused with a time-varying covari-
ate, which is a variable whose value is not fixed over
time, such as smoking status. Indeed, a person can be a
non-smoker, then a smoker, then a non-smoker. Note
however, that a variable may be both time-varying and
have an effect that changes over time.
In a Cox PH model, the HR is estimated by consider-
ing each time t a tw h i c ha ne v e n to c c u r s .W h e ne s t i -
mating the overall HR over the complete follow-up
period, the same weights are given to the very early HR
which affect almost all individuals and to very late HR
affecting only the very few individuals still at risk. The
HR is thus averaged over the event times. In the case of
proportional hazards, the overall HR is not affected by
this weighting procedure. If, on the other hand, the HR
changes over time, that is, the hazard rates are not pro-
portional, then equal weighting may result in a non-
representative HR, and may produce biased results [22].
It should be noted that the HR is averaged over the
event times rather than over the follow-up time. It is
unchanged if the time scale is changed without disturb-
ing the ordering of events.
Example
We applied some of the presented methods to breast
cancer patients as time-varying effects have been
reported, such as for nodal or hormone receptor status,
[23-26]. We studied women with non-metastatic, oper-
able breast cancer who underwent surgery between 1989
and 1993 at our institution, and who did not receive
previous neoadjuvant treatment. Exclusion criteria
included a previous history of breast carcinoma, concur-
rent contralateral breast cancer, and pathologic data
missing. Follow-up was performed according to the Eur-
opean Good Clinical Practice requirements and con-
sisted of regular physical examinations, and annual X-
ray mammogram, and additional assessments in case of
suspected metastases. Clinical and pathological charac-
teristics were analyzed according to the hospital-
recorded file at the time of treatment initiation. Patholo-
gical tumour size (≤ or > 20 mm) was measured on
fresh surgical specimens. A modified version of the
Scarff-Bloom-Richardson grading system was used (SBR
grade I, II, or III). PVI (Yes, No) was defined as the pre-
sence of neoplastic emboli within unequivocal vascular
lymphatic or capillary lumina in areas adjacent to the
breast tumour. Exploratory immuno-histochemical ana-
lyses were performed on a tissue microarray (TMA) to
assess hormone receptor (HRec) status (positive if ER-
positive and/or progesterone receptor [PgR]-positive).
ER and PgR expression levels were evaluated semi-quan-
titatively according to a standard protocol with cut-off
values at 10% positive tumor cells. Her2 expression level
was evaluated according to the Herceptest scoring sys-
tem [27]. Mib1 expression level was evaluated semi-
quantitatively. Information on all factors was available
for 979 women (Table 1). The median follow-up time
was 14 years (95% confidence interval: 13.7 - 14.2) and
264 women developed metastases.
Working example
The prognostic factors were initially selected based on
current knowledge regarding risk of metastases. They
were next analyzed using a conventional Cox regression
model; all were statistically significant at the 5% level in
Table 1 Characteristics of the study population.
N (%)
Year of diagnosis
1989 231 23.6
1990 207 21.1
1991 182 18.6
1992 189 19.3
1993 170 17.4
Metastases following surgery
Yes 264 27.0
No 715 73.0
Age at diagnosis
≤ 40 years 76 7.8
> 40 years 903 92.2
SBR Grade
Grade I 275 28.1
Grade II 444 45.3
Grade III 260 26.6
Tumor size
≤ 20 mm 753 76.9
> 20 mm 226 23.1
Lymph node involvement
No 554 56.6
Yes 425 43.4
Peritumoral vascular invasion
No 700 71.5
Yes 279 28.5
Hormone Receptor status
Both ER- and PR- 178 18.2
At least ER+ or PR+ 801 81.8
Her2 status
Positive 100 10.2
Negative 879 89.8
Mib1 status
Negative 691 70.6
Positive 288 29.4
Bellera et al. BMC Medical Research Methodology 2010, 10:20
http://www.biomedcentral.com/1471-2288/10/20
Page 3 of 12the univariate analyses, and were then entered onto a
multivariate Cox model. The risk of metastases was
increased for women with younger age compared to
older age; grade II and III tumours compared to grade I
tumours; large compared to small tumour sizes; lymph
node involvement comparedt on oi n v o l v e m e n t ;a n d
PVI compared to no PVI (Additional file 1: Estimated
log hazard ratios (log(HR)), and hazard ratios (HR = exp
( ˆ   )) with 95% confidence intervals (95% CI) and p-
values for model covariates when fitting a multivariate
conventional Cox model and a Cox model with time-by-
covariate interactions.). Based on this model, all vari-
ables, but hormone receptor, Her2 and Mib1 status, sig-
nificantly affected the risk of metastases.
Assessing non-proportionality: Graphical strategy
I nt h ep r e s e n c eo fac a t e g o r i c a lv a r i a b l e ,o n ec a np l o t
the Kaplan-Meier survival distribution, S(t), as a func-
tion of the survival time, for each level of the covariate.
If the PH assumption is satisfied, the curves should stea-
dily drift apart. One can also apply a transformation of
the Kaplan-Meier survival curves and plot the function
log(-log(S(t))) as a function of the log survival time,
where log represents the natural logarithm function. If
the hazards are proportional, the stratum specific log-
minus-log plots should exhibit constant differences, that
is be approximately parallel. These visual methods are
simple to implement but have limitations. When the
covariate has more than two levels, Kaplan-Meier plots
are not useful for discerning non-proportionality
because the graphs become to cluttered [10]. Similarly,
although the PH assumption may not be violated, the
log-minus-log curves are rarely perfectly parallel in prac-
tice, and tend to become sparse at longer time points,
and thus less precise. It is not possible to quantify how
close to parallel is close enough, and thus how propor-
tional the hazards are. The decision to accept the PH
hypothesis often depends on whether these curves cross
each other. As a result, the decision to accept the PH
hypothesis can be subjective and conservative [28], since
one must have strong evidence (crossing lines) to con-
clude that the PH assumption is violated. In view of
these limitations, some suggest providing standard
errors to these plots [29]. This approach however can
be computationally intensive and is not directly available
in standard computer programs. Kaplan-Meier and log-
minus-log plots are available from most standard statis-
tical packages (Table 2).
Working example (cont’)
Kaplan-Meier survival curves and log-minus-log plots
are shown for some variables (Figures 1 and 2). The
Kaplan-Meier survival curves appeared to steadily drift
apart for all but the hormone receptor status, Her2 sta-
tus, and mib1 status. The log-minus log plots looked
approximately parallel for Age, size of the tumour,
lymph node involvement, and PVI. Again, plots for the
hormone receptor status, Her2 status, and mib1 status
tended to indicate a violation of the PH assumption.
There was also some suspicion with respect to the SBR
grade.
Assessing non-proportionality: Modelling and testing
strategies
Graphical methods for checking the PH assumption do
n o tp r o v i d eaf o r m a ld i a g n o s t i ct e s t ,a n dc o n f i r m a t o r y
approaches are required. Multiple options for testing
and accounting for non-proportionality are available.
Cox proposed assessing departure from non-propor-
tionality by introducing a constructed time-dependent
variable, that is, adding an interaction term that involves
time to the Cox model, and test for its significance [1].
Suppose one is interested in evaluating if some variable
X has a time-varying effect. A time-dependent variable
is created by forming an interaction (product) term
between the predictor, X (continuous or categorical),
and a function of time t (f(t) = t, t
2, log(t), ...). Adding
this interaction to the model (equation 2), the hazard
then becomes:
ht ht x x f t x() () e x p [ ..() ]  0  (5)
The hazard ratio is given by HR(t) = hx+1(t)/hx(t) =
exp[b + g.x.f(t)] for a unit increase in the variable X,
and is time-dependent through the function f(t). If g >0
(g < 0), then the HR increases (decreases) over time.
Testing for non-proportionality of the hazards is
Table 2 Statistical software
R/Splus
© SAS
© SPSS
© Stata
©
Graphical checks survfit function lifetest procedure Survt command sts command
Time-by-
covariate
interactions
programming required. phreg procedure (definition of
interactions)/test statement.
time program command (definition of
interactions)/cox reg command.
tvc option/stcox
command
Scaled Schonfeld
residuals
cox.zph function phreg procedure/ressch option Not directly available/programming
required
stphtest command
Cumulative
residuals
Timereg/gof libraries/
cum.residuals function
phreg procedure/assess
statement/ph option
Not directly available/programming
required
Not directly available/
programming required
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zero. One can use different time functions such as poly-
nomial or exponential decay but often very simple fixed
functions of time such as linear or logarithmic functions
are preferred [28]. This modeling approach also provides
estimates of the hazard ratio at different time points
since values t of time can be fitted into the hazard ratio
function. Time-dependent variables provide a flexible
method to evaluate departure from non-proportionality
and an approach to building a model for the depen-
dence of relative risk over time. This approach however
should be used with caution. Indeed, if the function of
time selected is mis-specified, the final model will not
be appropriate. This is a disadvantage of this method
over more flexible approach.
Working example (cont’)
We created time-by-covariate interactions for each vari-
able of the model, by introducing products between the
variables and a linear function of time. As shown in
Additional File 1 (Estimated log hazard ratios (log(HR)),
and hazard ratios (HR = exp( ˆ   )) with 95% confidence
intervals (95% CI) and p-values for model covariates
when fitting a multivariate conventional Cox model and
a Cox model with time-by-covariate interactions.), sig-
nificant time-by-covariate interactions involved the SBR
grade, hormone receptor status, Her2 status, and PVI (p
< 0.05). Thus these results indicated that the hazard
ratios associated with these factors were not constant
over time. The parameters ( ˆ   ) associated with most
interactions were negative, suggesting that the hazard
ratios were decreasing over time. The estimated hazard
ratio associated with an SBR grade II (versus grade I) as
a function of time t was given by: HR(t) = exp(1.71 -
0.14t). Hazard ratios were 4.8, 3.6, and 2.7 at respec-
tively 1, 3, and 5 years. Similarly, the estimated hazard
ratio associated with the hormone receptor status was:
HR(t) = exp(0.73 - 0.14t), that is hazard ratios of 1.8,
1.3, and 1.0 at respectively 1, 3, and 5 years. While the
conventional Cox model did not show any significant
effect for hormone receptors, Her2 and Mib1, these
variables had a significant effect once time-by-covariate
interactions were included.
Departure from non-proportionality can also be inves-
tigated using the residuals of the model. A residual
Figure 1 Kaplan-Meier survival curves for SBR grade, tumour size, PVI, hormone receptor status.
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the expected data under the assumption of the model.
Schoenfeld residuals are calculated and reported at
every failure time under the PH assumption, and as
such are not defined for censored subjects [15,30]. They
are defined as the covariate value for the individual that
failed minus its expected value assuming the hypotheses
of the model hold. There is a separate residual for each
individual for each covariate. A smooth plot of the
Schoenfeld residuals can then be used to directly visua-
lize the log hazard ratio [15]. Assuming proportionality
of the hazards, the Schoenfeld residuals are independent
of time. Thus, a plot suggesting a non-random pattern
against time is evidence of non-proportionality. Graphi-
cally, this method is more reliable and easier to interpret
than plotting the log(-log(S(t)) function presented ear-
lier. The presence of a linear relationship with time can
be tested by performing a simple linear regression and a
test trend. A slope significantly different from zero
would be evidence against proportionality: an increasing
(decreasing) trend would indicate an increasing
(decreasing) hazard ratio over time. It is recommended
to carefully look at the residual plot in addition to
performing this test as some patterns may be apparent
on the plots (quadratic, logarithmic), but remain unde-
tected by the statistical test. Moreover, undue influence
of outliers might become obvious [10]. Although, the
method based on the smoothed Schoenfeld residuals
provides time-dependent estimates, it can have some
drawbacks [14,18]. The uncertainty estimates associated
with the resulting time-dependent estimates can be diffi-
cult to use in practice, and the estimator provided may
not have good statistical properties, such as consistency.
Importantly, p-values resulting from trend tests based
on the Schoenfeld residuals are obtained independently
for each covariate of the model, assuming the Cox
model is justified for the other covariates of the model;
as such, results should be interpreted carefully. Tests
based on the Schoenfeld residuals can be easily imple-
mented in most standard statistical packages (Table 2).
Working example (cont’)
For each covariate, scaled Schoenfeld residuals were
plotted over time, and tests for a zero slope were per-
formed. The corresponding p-values, as well as the p-
value associated with a global test of non-proportionality
are reported in Table 3. The global test suggested strong
Figure 2 Log(-log(survival)) curves as a function of time (log scale) for SBR grade, tumour size, PVI, hormone receptor status.
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that deemed most likely to contribute to non-propor-
tionality were the SBR grade (p < 0.01), PVI (p = 0.05)
and hormone receptor status (p = 0.05). These numeri-
cal findings suggest a non constant hazard ratio for
these variables. Residuals help visualizing the log hazard
ratio ˆ   over time for each covariate (figure 3). We
added dashed and dotted lines representing respectively
the null effect (null log hazard ratio) and the averaged
log hazard ratio estimated by the conventional Cox
model. With respect to the SBR grade, the plots sug-
gested strong effect over the first five years. This effect
tended to diminish afterwards. Similarly, the impact of
PVI changed over time, with again higher risks of
metastases in the early years, and then this effect tended
to vanish. Concerning hormone receptor status, plots
suggested that a negative status increased the risk of
metastases early on, and became protective afterwards.
The cumulative sum of Schoenfeld residuals, or
equivalently the observed score process can also be used
to assess proportional hazards [31]. Graphically, the
observed score process is plotted versus time for each
variable of the model, together with simulated processes
assuming the underlying Cox model is true, that is,
assuming proportional hazards. Any departure of the
observed score process from the simulated ones is evi-
dence against proportionality. These plots can then be
used to assess when the lack of fit is present. In particu-
lar, an observed score well above the simulated process
is an indication of an effect higher than the average one,
and conversely. This method is particularly well illu-
strated in a recent publication by Cortese et al. [18].
Goodness-of-fit tests can be implemented based on the
cumulative residuals. The cumulative residuals based
approach overcomes some drawbacks encountered with
the Schoenfeld residuals, since resulting estimators tend
to have better statistical properties, and justified p-
values are derived [14]. The cumulative residuals
approach is implemented in some standard statistical
packages (Table 2).
Working example (cont’)
Tests based on cumulative residuals are presented in
Table 4. At the 5% significance level, test statistics sug-
gest non-constant effect over time for the grade of the
tumor, as well as the status of the hormone receptors,
h e r 2 ,a n dM i b 1 .F o ri l l u s t r a t i o n ,w ea l s op l o t t e dt h e
resulting score process for some variables (Figure 4). In
accordance with the test statistics based on the cumula-
tive residuals, we observe strong departure of the
observed processes from the simulated curves under the
model for the grade and hormone receptor status. These
plots are particularly useful in identifying where the lack
of fit is present. For example, the initial positive score
process associated with hormone receptors, suggests
that the effect of this variable is initially higher than the
average effect, and thus lower than the average effect
afterwards. That is, the risk of metastases is increased
initially for women with both negative hormone recep-
tors compared to the average risk, and decreased
afterwards.
Another simple approach for testing time-varying
effects of covariates involves fitting different Cox models
for different time periods. Indeed, although the PH
assumption may not hold over the complete follow-up
period, it may hold over a shorter time window. Unless
there is an interest in a particular cut-off time value,
two subsets of data can be created based on the median
event time [10]. That is, a first analysis is conducted by
censoring everyone still at risk beyond this time point,
and a second one by considering only those subjects
still at risk thereafter. In such case, the interpretation of
the models is conditional on the length of the survival
time, and results should thus be interpreted with cau-
tion. Even if the period of analysis is shortened, one
should still ensure that the PH assumption is not vio-
lated within these reduced time periods. Moreover,
since fewer event times are considered, analyses can suf-
fer from a decreased power. Finally, although this
method is particularly simple to implement and might
provide sufficient information in some settings, that is if
one is interested in a short time window, it should be
noted that this method is not directly testing the PH
assumption, and a different parametrization would be
needed to perform such a test.
Working example (cont’)
The median event time was 4.3 years. A Cox model was
applied censoring everyone still at risk after 4.3 years,
while only those subjects still at risk beyond this time
point were included in another model (Additional file 2:
Estimated hazard ratios (exp( ˆ   )) with 95% confidence
intervals (95% CI) and p-values for model covariates in
two independent Cox models for two different time
Table 3 Test for non-proportionality based on the scaled
Schoenfeld residuals from the conventional Cox model
(see table 1).
Variable p-value
Age 0.10
Grade II <0.01
Grade III <0.01
Size 0.32
Lymph node involvement 0.22
PVI 0.05
Hormone receptor 0.05
Her2 0.08
Mib1 0.07
GLOBAL <0.01
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cant in the first model as negative hormone receptor
status, positive Her2 status and Mib1 positive status
were associated with an increased risk of metastases. In
women still at risk past 4.3 years, younger age, greater
tumor size, and lymph node involvement were asso-
ciated with an increased risk of metastases. The effects of
other variables have disappeared. Interestingly, hormone
receptor negative status had a significant protective effect
in this second model (HR = 0.5), while the first analysis
suggested a significant increased risk for (HR = 1.7).
Tests for non-proportionality based on the cumulative
residuals suggested a persistent time-varying effect of the
grade for the analysis restricted to the first 4.3 years.
It is also possible to account for non-proportionality by
partitioning the time axis as proposed by Moreau et al.
[32]. The time axis is partitioned and hazard ratios are
then estimated within each interval. Thus, testing for
non-proportionality is equivalent to testing if the time-
specific HR are significantly different. Results can how-
ever sometimes be driven by the number of time intervals
[33], and time intervals should thus be carefully selected.
Figure 3 Scaled Schoenfeld residuals for SBR grade, PVI, and hormone receptor status (with 95% confidence interval).
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and as such, the Cox model, is another option. Indeed,
other powerful statistical models are available to account
for time-varying effects, including additive models,
accelerated failure time models, regression splines mod-
els or fractional polynomials [33-36].
Finally, one can perform a statistical analysis stratified
by the variable suspected to have a time-varying effect;
this variable should be thus categorical or be categor-
ized. Each stratum k has a distinct baseline hazard but
common values for the coefficient vector b,t h a ti s ,t h e
hazard for an individual in stratum k is hk(t) = exp(bx)
Stratifying assumes that the other covariates are acting
in the same way in each stratum, that is, HRs are similar
across strata. Although stratification is effective in
removing the problem of non-proportionality and sim-
ple to implement, it has some disadvantages. Most
importantly, stratification by a non-proportional variable
precludes estimation of its strength and its test within
the Cox model. Thus, this approach should be selected
if one is not directly interested in quantifying the effect
of the variable used for stratification. Moreover, a strati-
fied Cox model can lead to a loss of power, because
more of the data are used to estimate separate hazard
functions; this impact will depend on the number of
subjects and strata [10]. If there are several variables
with time-varying risks, this would require the model to
Table 4 Test for non-proportionality based on the
Cumulative residuals from the conventional Cox model
(see table 1).
Variable p-value
Age 0.97
Grade II 0.02
Grade III <0.01
Size 0.16
Lymph node involvement 0.75
PVI 0.11
Hormone receptor <0.01
Her2 <0.01
Mib1 <0.01
Figure 4 Observed score process for SBR grade, lymph node involvement, and hormone receptor status (with 95% confidence interval).
Bellera et al. BMC Medical Research Methodology 2010, 10:20
http://www.biomedcentral.com/1471-2288/10/20
Page 9 of 12be stratified on these multiple factors, which again is
likely to decrease the overall power.
Discussion
While ensuring that the PH assumption holds is part of
the modeling process, it is also useful in providing valu-
able information on time-varying effects. In our illustra-
tive example, the conventional Cox model suggested
that all factors but HRec, Her2, and Mib1 status were
strong prognostic factors of metastases. Additional tests
indicated that the PH assumption was not satisfied for
some variables of the model. Tumour grade had a sig-
nificant time-varying effect, but although its effect
diminished over time, it remained strong. According to
the conventional model hormone receptor status did
not significantly impact relapses. Additional tests pro-
vided strong evidence of a time-varying effect. Impor-
tantly, both tests based on residuals suggested that
negative hormone receptor status increased the risk of
metastases early but became protective thereafter, in
accordance with the analysis partitioned on event time.
This reversal of effect may explain the non-significant
averaged hazard ratio provided by the conventional Cox
model and reported earlier [26].
Applying a Cox model without ensuring that its
underlying assumptions are validated can lead to nega-
tive consequences on the resulting estimates [28,37]. For
variables not satisfying the non-proportionality assump-
tion, the power of the corresponding tests is reduced,
that is, we are less likely to conclude for a significant
effect when there is actually one. If the hazard ratio is
increasing over time, the estimated coefficient assuming
PH is overestimating at first and underestimating later
on. For those variables of the model with a constant
hazard ratio, the power of tests is also reduced as a con-
sequence of an inferior fit of the model.
Once non-proportionality is established, time-depen-
dency can be accounted for in different ways. The strat-
egy will depend on the study objectives. If there is no
interest in longer time periods, one can shorten the fol-
low-up time as non-proportionality is less likely to be
an issue on short time intervals. If there is no particular
interest in the variable with the time-varying effect, one
could stratify on this variable in the statistical analysis,
however no association between the stratification vari-
able and survival can be tested. If one wants to describe
t h ee f f e c to ft h ev a r i a b l eo v e rt i m e ,i ti sp o s s i b l et or e l y
on time by covariate interactions or on plots of residuals
to estimate of relative risks at different time points.
Methods to test and account for non-proportionality are
available in most standard statistical software (Table 2).
It is difficult to propose definite guidelines for the best
s t r a t e g yf o rt e s t i n gf o rn o n - p r o p o r t i o n a l i t y .E a c h
method has its advantages and limitations, and
depending on the study objective some approaches
might be preferred. Before performing statistical model-
ing, the study objectives should be clearly stated in
advance, as well as the statistical tests that will be
employed. Departure from non-proportionality can be
investigated using graphical and numerical approaches.
Plotting methods involve visualizing the Kaplan-Meier
survival curves for the variable tested for non-propor-
tionality. This graphical method requires categorical
variables, and is particularly appropriate for binary data;
h o w e v e rt h e yd on o tp r o v i d ef o r m a ld i a g n o s t i ct e s t s .
Numerical tests involve for example testing for covari-
ate-by-time interactions orf o rt h ep r e s e n c eo fat r e n d
in the residuals of the model. Including a covariate-by-
time interaction is particularly simple within the Cox
model; however, results are strongly dependent on the
choice of the functional form of the time function. Tests
based on cumulative residuals tend to have better statis-
tical properties than those based on the Schoenfeld resi-
duals. As a result, performing a test based on the
cumulative residuals seems to be a more powerful
approach in detecting covariates with time-varying
effects.
Note that the Cox model involves multiple types of
residuals including the martingale, deviance, score and
Schoenfeld residuals, which can be particularly useful as
additional regression diagnostics for the Cox model.
Martingale residuals are useful for determining the func-
tional form of a covariate to be included in the model
and deviance residuals can be used to examine model
accuracy. Additional details can be found in [10,11].
Statistical testing raises the issue of power, that is, the
ability of tests to find true effects. We have seen for
example that some simple strategies, such as shortening
the observation period can suffer from reduced power
as fewer events are considered. This might be a limita-
tion with small datasets. Simulations have shown that
stratified Cox modeling usually leads to wider confi-
dence intervals, that is, reduced power compared to
unstratified analysis [38]. Statistical tests for time-vary-
ing effects have different power to detect non-propor-
tionality. It has been shown that tests requiring
partitioning of the failure time have less power than
other tests, while tests based on time-dependent covari-
ates or on the Schoenfeld residuals have equally good
power to detect non-proportionality in a variety of non-
proportional hazards and are practically equivalent [17].
The issue of power naturally leads to the question of
sample size. Clinical trials are usually designed with just
enough power to detect the treatment effect. In this
context, one should not expect to have enough details
about the actual shape of the HR over time. Assuming a
trial designed with an 80% power to detect a treatment
effect, Therneau and Grambsch showed that the test
Bellera et al. BMC Medical Research Methodology 2010, 10:20
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tionality, but could not distinguish between a linear and
ad i s c r e t ei n c r e a s eo ft h eh a z a r dr a t i oo v e rt i m e[ 1 0 ] .
Observational studies are usually designed for explora-
tory analyses and do not rely on a formal estimation of
the sample size. There might not always be enough
power to detect a specific time trend. The question of
lack of power should not be interpreted as an argument
against testing for non-proportionality. Just as any other
statistical model, one should ensure that major assump-
tions are not violated.
Since its original publication in 1972, the Cox propor-
tional-hazards model has gained widespread use and has
become a popular tool for the analysis of survival data
in medicine. After performing an online search, we
found that the original paper by Cox had been cited
approximately 25, 000 times, with about 8, 000 citations
in oncology papers [4]. While time dependency has
been accounted for and reported in oncology publica-
tions, such as in breast or colon cancer studies
[26,33,39-42,42], the verification of the PH assumption
is unfortunately far from being systematic. In a 1995
review of five clinical oncology journals including about
130 papers, Altman et al. reported that only 2 out of the
43 papers which relied on a Cox model, mentioned that
the PH assumption was verified [2]. Similarly, about ten
years later Mathoulin et al. assessed the quality of
reporting of survival events in randomized clinical trials
in eight general or cancer medical journals [3]. The
authors reported that only one of the 64 papers that
used a Cox model mentioned verifying the PH
assumption.
Our objective was to familiarize the reader with the
PH assumption. We also highlighted that detecting and
accounting for time-varying effects provide insights on
some specific time patterns and valuable biological
information that could be missed otherwise. Given the
possible consequences on parameter estimates, checking
the proportionality of hazards should be an integral part
of a survival analysis based on a Cox model. In the pre-
sence of variables with time-varying risks, plots should
be used to augment the results and indicate where non-
proportionality is present. This seems particularly
appropriate in the context of oncology studies, as long
follow-ups are common and non-constant hazards have
already been reported.
Conclusions
Investigating time-varying effects should be an integral
part of Cox survival analyses. Detecting and accounting
for time-varying effects provide insights on some speci-
fic time patterns, and on valuable biological information
that could be missed otherwise.
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